Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from JD Health International, Inc. ( (HK:6618) ).
JD Health International Inc. has announced significant advancements in its operations during the first quarter of 2025. The company launched several innovative drugs online and strengthened partnerships with major healthcare product companies to expand its product offerings and market reach. Additionally, JD Health made strides in medical AI, introducing the ‘AI Jingyi’ system and open-sourcing its ‘Jingyi Qianxun’ LLM, which have been well-received by healthcare professionals. Financially, the company reported a 25.5% increase in revenue and a 47.7% rise in non-IFRS profit compared to the same period in 2024, indicating strong growth and operational success.
The most recent analyst rating on (HK:6618) stock is a Buy with a HK$46.30 price target. To see the full list of analyst forecasts on JD Health International, Inc. stock, see the HK:6618 Stock Forecast page.
More about JD Health International, Inc.
JD Health International Inc. operates in the healthcare industry, focusing on providing online healthcare services and products. The company is known for its online marketplace for new and specialty drug launches and collaborates with leading healthcare product companies to enhance product innovation and supply chain efficiency.
Average Trading Volume: 21,434,219
Technical Sentiment Signal: Buy
Current Market Cap: HK$121.4B
See more insights into 6618 stock on TipRanks’ Stock Analysis page.